Method for researching postoperative enteroparalysis symptom by using Wudai granule drug-containing serum

By studying the chemical composition and mechanism of drug-containing serum of Wuda Granules, differentially expressed genes were identified and pharmaceutical compositions were prepared, the problem of insufficient effectiveness of postoperative intestinal paralysis treatment was solved, and the function of SMC cells was significantly improved, and the function of SMC cells was provided. New treatment pathways and reduce adverse reactions.

CN118910235AInactive Publication Date: 2024-11-08GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410942028.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing technology lacks effective active intervention measures to solve the symptoms of postoperative intestinal paralysis, and the progress of traditional Chinese medicine research is slow, and there is a lack of relevant research on drug-containing serum of Wuda Granules, resulting in less obvious treatment effects and the existence of adverse reactions.

Method used

By studying the chemical composition and mechanism of action in the drug-containing serum of Wuda Granules, the components were identified by high-performance liquid phase method, and RNA-seq experiments were conducted in SMC cell lines to identify 12 differentially expressed genes and provide drug compositions. Preparation methods, including capsules, granules, etc., are used to treat postoperative intestinal paralysis.

Benefits of technology

The effective ingredients and mechanism of action in Wuda Granule's drug-containing serum were successfully identified, which significantly improved the physiological function of SMC cells, provided a new drug development and research path for the treatment of postoperative intestinal paralysis, and reduced the occurrence of adverse reactions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910235A_ABST
    Figure CN118910235A_ABST
Patent Text Reader

Abstract

The invention relates to a method for researching postoperative enteroparalysis symptoms by using Wudai particle drug-containing serum, and belongs to the technical field of biochemistry and molecular biology. According to the invention, the medicinal value of the Wudai granule drug-containing serum on the postoperative enteroparalysis symptom is determined, so that a foundation is laid for breaking through the postoperative enteroparalysis symptom. The morphological and functional changes of the smooth muscle cell structure after administration, especially the expression level conditions of 12 differential expression genes in the cell, are clarified, and data support is provided for further exploration of the action mechanism of the Wudao particle drug-containing serum.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biochemistry and molecular biology, and in particular to a method for studying the effect of Wuda granule-containing serum on postoperative ileus (POI) symptoms. Background Art

[0002] The concept of postoperative intestinal paralysis generally refers to temporary gastrointestinal motility disorders after surgery. Postoperative intestinal paralysis is one of the common complications after abdominal surgery. Its pathophysiological mechanism is multifactorial, including surgical trauma, inflammation, edema, nerve damage, etc., and one of the important mechanisms is that tissue trauma caused by surgical operation can lead to the release of a large number of cytokines and inflammatory mediators.

[0003] Postoperative patients often experience complications such as gastrointestinal dysfunction. There is currently a general lack of effective proactive intervention measures for these complications, and the clinical efficacy is not obvious, and even adverse reactions occur. It is necessary to find ideas and paths to solve these clinical problems from a theoretical perspective.

[0004] Traditional Chinese medicine classifies the symptoms of postoperative gastrointestinal dysfunction as "intestinal paralysis" and "intestinal knots". Intestinal dysfunction causes distension and pain, and resistance to pressure, constipation, or dysfunction of the spleen and stomach, and mixed food and water go down. The main pathogenesis is the disorder of the ascending and descending of qi, and the main treatment method is to regulate the ascending and descending, dredge the qi to unclog the three burners. Traditional Chinese medicine has the advantages of few adverse reactions and obvious effects in treating postoperative complications.

[0005] For example, patent CN1628815A discloses the application of rhubarb decoction combined with Dachengqi decoction in the treatment of postoperative inflammatory intestinal obstruction. The rhubarb decoction with the effects of clearing the interior, promoting blood circulation and removing blood stasis, clearing away heat and detoxifying, antibacterial and promoting intestinal peristalsis is injected through a stomach tube and combined with a compound Dachengqi decoction with retention enema to promote the absorption of inflammatory adhesions in patients with intestinal obstruction by promoting the intestinal activity of the patient to accelerate the absorption of inflammation and assist in the relief of obstruction to achieve the purpose of treatment. CN106668389A discloses a Chinese medicine composition for promoting postoperative gastrointestinal function recovery and preventing and treating postoperative intestinal paralysis and its preparation method. The oral Chinese medicine preparation is extracted, concentrated and prepared by combining traditional decoction method with modern preparation technology; it can effectively promote the recovery of gastrointestinal function and prevent and treat postoperative intestinal paralysis in patients after surgery, and reduce their economic burden.

[0006] Currently, there is no relevant research on the effect of WuDa Granule-containing serum on postoperative gastrointestinal dysfunction. Therefore, exploring the chemical composition and mechanism of action of WuDa Granule-containing serum has profound significance for the screening and development of drugs for postoperative gastrointestinal dysfunction. Summary of the invention

[0007] The purpose of the present invention is to provide a research method for the effect of Wuda granule medicated serum on postoperative intestinal paralysis (POI) symptoms. The present invention clarifies the medicinal value of the drug components in Wuda granule medicated serum on postoperative intestinal paralysis (POI) symptoms, laying a foundation for a breakthrough in the treatment of postoperative intestinal paralysis (POI) symptoms, especially the expression levels of 12 differentially expressed genes in cells, providing data support for the next step of exploring the mechanism of action of Wuda granule medicated serum.

[0008] On the one hand, the present invention provides a method for studying the effect of Wuda granules-containing serum on postoperative intestinal paralysis (POI) symptoms, comprising the following steps:

[0009] Step S1, after gavage of the WuDa Granule aqueous solution to healthy animals, plasma containing the WuDa Granules was taken to prepare WuDa Granule drug-containing serum;

[0010] Step S2, detecting drug components in drug-containing serum;

[0011] Step S3: The primary cultured SMC cell line was cultured with the WuDa Granules-containing serum obtained in step S2, and the RNA-seq experiment was completed.

[0012] Preferably, the drug-containing serum contains norisoboldine and arecoline.

[0013] Preferably, the drug-containing serum contains ginsenoside Rc, ginsenoside Rd, quercetin, isoquercetin, norisoboldine, arecoline and amygdalin.

[0014] Preferably, in step S2, the chemical components in the Wuda granules are detected by high performance liquid chromatography.

[0015] Preferably, in step S3, the RNA-seq experiment identified 12 differentially expressed genes, of which 4 were upregulated and 8 were downregulated.

[0016] Preferably, the four upregulated genes are ZC3H11A, STX16-NPEPL1, PTGES3L-AARSD1, and DISP1, in order.

[0017] The upregulated gene ZC3H11A is very important in the organism and has multiple functions, especially in development, immune response and viral replication. STX16-NPEPL1 gene abnormalities are closely related to gastrointestinal diseases, and upregulation protects the gastrointestinal tract. The PTGES3L-AARSD1 gene is expressed in immune cells and may be involved in immune response and T cell receptor signaling. The DISP1 gene plays an important role in the structure and functional homeostasis of biological tissues. Downregulated genes are closely related to tumors, metabolic disease occurrence, intracellular metabolism and apoptosis.

[0018] Preferably, the eight downregulated genes are ZBED6, BEST1, TCAF2, AC005324.3, PALM2-AKAP2, AL136295.4, STBD1, and AL355312.5.

[0019] On the other hand, the present invention provides a use of the aforementioned WuDa granule-containing serum in the preparation of a pharmaceutical composition for postoperative intestinal paralysis, wherein the pharmaceutical composition contains a pharmacologically acceptable pharmaceutical excipient.

[0020] Preferably, the dosage form of the pharmaceutical composition includes capsules, granules, powders, pills, tablets, injections, and lyophilized powders.

[0021] Preferably, the pharmaceutical composition is used in any proportion / single drug / combination for preparing a preparation for treating postoperative intestinal paralysis (POI).

[0022] The present invention has the beneficial effects as follows: the present invention uses high performance liquid chromatography to identify the chemical components in the Wuda granule medicated serum, and treats SMC cells with the medicated serum, so that the physiological functions of the SMC cells tend to be normal, indicating that the Wuda granule medicated serum can be used to treat postoperative intestinal paralysis symptoms.

[0023] For a long time, due to technical limitations and the complexity of Chinese medicine ingredients, the research on Chinese medicine pharmacology has been slow. The present invention studies the components of WuDa granule aqueous solution, analyzes its effective medicinal components and possible mechanisms of action, laying a foundation for the subsequent development of postoperative intestinal paralysis (POI) drugs, and provides new tools for subsequent research on postoperative intestinal paralysis (POI) discovery, therapeutic drugs, and treatment prognosis evaluation. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 Volcano plot of differential expression. DETAILED DESCRIPTION

[0025] In order to enable those skilled in the art to better understand the technical solution of the present invention, some non-limiting embodiments are further disclosed below to further illustrate the present invention in detail.

[0026] The experimental methods of the present invention, unless otherwise specified, are all conventional technical methods in the art and are performed in accordance with the technical conditions described in professional literature or relevant product instructions; the materials, reagents, etc. used, unless otherwise specified, can be obtained from commercial channels.

[0027] Example 1

[0028] Experimental methods:

[0029] SD rats were divided into two groups, 10 normal control group and 10 Wuda granule group. The normal control group was gavaged with normal saline twice a day; the aqueous solution obtained by dissolving Wuda granules in water was gavaged at 1500 mg / kg twice a day, and blood was collected after 7 consecutive days of administration, and plasma was obtained after centrifugation for later use.

[0030] After each sample tube was left to stand at room temperature for 2 hours to completely coagulate, it was centrifuged at 6000r / min for 10 minutes to separate the serum, inactivated in a 56°C water bath for 20 minutes, sterilized by filtration with a 0.22μm microporous filter membrane, and stored at -20°C for future use;

[0031] UPLC system: Ultimate3000 ultra-high performance liquid chromatography system was used for detection;

[0032] Chromatographic conditions are as follows: Chromatographic column: Acquity BEHAmide column, specifications: 1.7μm2.1×100mm; mobile phase: mobile phase A (water-methanol solution (the volume ratio of water to methanol is 2:1)) and mobile phase B (acetonitrile); gradient elution program: 0.00 to 2.00 minutes, 95 volume% mobile phase B; 2.00 to 5.00 minutes, 93 volume% mobile phase B; 5.00 to 6.00 minutes, 75 volume% mobile phase B; 6.00 to 6.1 minutes, 95 volume% mobile phase B; 6.10 to 10.00 minutes, 95 volume% mobile phase B, wherein the total amount of mobile phase A and mobile phase B is 100 volume%.

[0033] Flow rate: 0.1 mL / min; column temperature: 40°C; autosampler temperature: 10°C; injection volume: 5 μL

[0034] Experimental results:

[0035] Seven compounds (ginsenoside Rc, ginsenoside Rd, quercetin, isoquercetin, norisoboldine, arecoline, amygdalin) were identified in the plasma of Wuda granules after administration. The specific peak positions and other information are shown in Table 1 below:

[0036] Table 1 The components of Wuda Granules drug-containing serum

[0037] Serial number <![CDATA[t R (min)]]> Molecular formula Δppm Identification 1 6.71 <![CDATA[C 53 H 90 O 22 ]]> 1.689 Ginsenoside Rc 2 6.97 <![CDATA[C 48 H 82 O 18 ]]> 0.009 Ginsenoside Rd 3 5.82 <![CDATA[C 21 H 20 O 11 ]]> -0.189 Quercetin 4 5.51 <![CDATA[C 21 H 20 O 12 ]]> 0.152 Isoquercetin 5 4.78 <![CDATA[C 18 H 19 NO 4 ]]> -0.14 Desmethylisoboldine 6 1.21 <![CDATA[C 8 H 13 NO 2 ]]> 0.735 Arecoline 7 4.93 <![CDATA[C 20 H 27 NO 11 ]]> -0.581 Amygdalin

[0038] It can be seen from Table 1 that after the drug composition entered the rat's body, some of the drug components had entered the blood. The relevant drug components of WuDa Granules were obtained by separation. After multiple identification and testing of the drug components, it was found that the active ingredients of WuDa Granules were stable and the quality was controllable, and they could be used for subsequent experiments.

[0039] Example 2

[0040] Experimental methods:

[0041] 1. RNA quality identification

[0042] The cultured smooth muscle cell SMC normal group and the drug-treated group (the drug-containing serum obtained by separating the blood of mice after oral administration of WuDa granules in Example 1 of the present invention) were centrifuged and collected for 3 biological replicates, and Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA). The total RNA quality detection method is as follows: (1) NanoDrop2000 spectrophotometer: to detect the purity and concentration of RNA; (2) Agient2100 / LabChip GX detection: to accurately detect the integrity of RNA.

[0043] 2. Library Construction

[0044] Only total RNA samples with RIN>6.5 and concentration ≥50 ng / μL were retained for the construction of sequencing libraries.

[0045] RNA sequencing libraries were constructed from the extracted RNA using standard Illumina library preparation protocols.

[0046] 3. RNA-seq

[0047] The sequencing was performed on the Illumina HiSeq X plus platform. For mRNA sequencing reads, we used Hisat2 with default parameters to map reads to the human genome (reference genome version information: Homo_sapiens.GRCh38_release95.genome.fa) and splice junction annotations. FPKM (Fragments Per Kilobase of transcript per Million fragments mapped) was used for normalization as an indicator to measure the expression level of transcripts or genes. Differential expression genes were screened based on the count value of genes in each sample using differential analysis software. For differential grouping with biological replicates, DESeq2 software was used for differential analysis. In the process of differential expression gene detection, Fold Change ≥ 1.5 and P value < 0.05 were used as screening criteria. A total of 12 differentially expressed genes were identified, of which 4 were upregulated and 8 were downregulated.

[0048] Experimental results: The results of differentially expressed genes are as follows Figure 1As shown, after the Wuda granules-containing serum of the present invention was used to act on SMC cells, differential analysis was performed using DESeq2, and a total of 12 differentially expressed genes were identified, of which 4 were upregulated and 8 were downregulated. The 4 upregulated genes were ZC3H11A, STX16-NPEPL1, PTGES3L-AARSD1, and DISP1; the 8 downregulated genes were ZBED6, BEST1, TCAF2, AC005324.3, PALM2-AKAP2, AL136295.4, STBD1, and AL355312.5. It can be seen that the Wuda granules-containing serum prepared by the present invention has a significant improvement effect on the structural and functional homeostasis of intestinal paralysis smooth muscle cells.

[0049] The method of the present invention has been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein within the content, spirit and scope of the present invention to implement and apply the technology of the present invention. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention.

Claims

1. A method for studying the effect of Wuda granule-containing serum on postoperative intestinal paralysis symptoms, comprising the following steps: Step S1, after gavage of the WuDa Granule aqueous solution to healthy animals, plasma containing the WuDa Granules was taken to prepare WuDa Granule drug-containing serum; Step S2, detecting drug components in drug-containing serum; Step S3: The primary cultured SMC cells were added with the WuDa Granules-containing serum obtained in step S2 and cultured, and the RNA-seq experiment was completed.

2. The research method according to claim 1, characterized in that: The drug-containing serum contains norisoboldine and arecoline.

3. The research method according to claim 2, characterized in that: The drug-containing serum contains ginsenoside Rc, ginsenoside Rd, quercetin, isoquercetin, norisoboldine, arecoline and amygdalin.

4. The research method according to claim 1, characterized in that: Step S2, detecting and identifying the chemical components in Wuda granules by high performance liquid chromatography.

5. The research method according to claim 1, characterized in that: In step S3, the RNA-seq experiment identified 12 differentially expressed genes, of which 4 were upregulated and 8 were downregulated.

6. The research method according to claim 5, characterized in that: The four upregulated genes are ZC3H11A, STX16-NPEPL1, PTGES3L-AARSD1, and DISP1; the eight downregulated genes are ZBED6, BEST1, TCAF2, AC005324.3, PALM2-AKAP2, AL136295.4, STBD1, and AL355312.

5.

7. Use of the WuDa granule-containing serum according to claim 1 in the preparation of a pharmaceutical composition for postoperative intestinal paralysis, wherein the pharmaceutical composition contains pharmacologically acceptable pharmaceutical excipients.

8. The use according to claim 7, characterized in that: The dosage forms of the pharmaceutical composition include capsules, granules, powders, pills, tablets, injections, and lyophilized powders.

9. The use according to claim 7, characterized in that: The pharmaceutical composition is used in any proportion / single drug / combination for preparing a preparation for treating postoperative intestinal paralysis.

Citation Information

Patent Citations

  • Method for determining medicine active component in serum

    CN102486472A

  • Preparation and identification method of traditional Chinese medicine serum for in-vitro cell culture

    CN114910573A

  • Application of Xihuang pill in preparation of medicine for promoting tumor blood vessel normalization

    CN118286287A